KatsikiNAthyrosVGKaragiannisAWierzbickiASMikhailidisDP. Should we expand the concept of coronary heart disease equivalents?Curr Opin Cardiol. 2014;29(4):389–395.
2.
DragerLFPolotskyVYLorenzi-FilhoG. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. 2011;140(2):534–542.
3.
NenaEPapanasNSteiropoulosP. Mean Platelet Volume and Platelet Distribution Width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity?Platelets. 2012;23(6):447–454.
4.
AnandamAPatilMAkinnusiMJaoudePEl-SolhAA. Cardiovascular mortality in obstructive sleep apnoea treated with continuous positive airway pressure or oral appliance: an observational study. Respirology. 2013;18(8):1184–1190.
5.
HolmqvistFGuanNZhuZ. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2015;169(5):647–654.e2.
6.
Sánchez-de-la-TorreMNadalNCortijoA. Role of primary care in the follow-up of patients with obstructive sleep apnoea undergoing CPAP treatment: a randomised controlled trial. Thorax. 2015;70(4):346–352.
7.
AltintasNMutluLAkkoyunD. Effect of CPAP on new endothelial function marker; endocan in people with obstructive sleep apnea. Angiology. doi: 10.1177/0003319715590558.
8.
BaltaSOzturkC. The relation between CD40 ligand and coronary artery disease. Cardiology. 2015;131(2):107–108.
9.
BaltaIBaltaSKoryurekOM. Mean platelet volume is associated with aortic arterial stiffness in patients with Behçet’s disease without significant cardiovascular involvement. J Eur Acad Dermatol Venereol. 2014;28(10):1388–1393.
10.
LeeWKuS-KKimS-WBaeJ-S. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229(5):620–630.
11.
SarrazinSAdamELyonM. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765(1):25–37.
12.
KaliAShettyKSR. Endocan: a novel circulating proteoglycan. Indian J Pharmacol. 2014;46(6):579–583.
13.
BechardDMeigninVScherpereelA. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000;37(5):417–425.
14.
BaltaSMikhailidisDPDemirkolS. Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773–777.
WangX-SYangWLuoTWangJ-MJingY-Y. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015;19(3):124–127.
17.
KoseMEmetSAkpinarTS. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology. doi: 10.1177/0003319714548870.
18.
YilmazMISiriopolDSaglamM. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86(6):1213–1220.
19.
BaltaIBaltaSKoryurekOM. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70(2):291–296.
20.
GowdaSGoldblumOMMcCallWVFeldmanSR. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol. 2010;63(1):114–123.
21.
BaltaIBaltaSDemirkolS. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5):1066–1070.
22.
KatsikiNAnagnostisPAthyrosVGKaragiannisAMikhailidisDP. Psoriasis and vascular risk: an update. Curr Pharm Des. 2014;20(39):6114–6125.
23.
CelıkTBaltaSKaramanM. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015;24(1):55–60.
